BACKGROUND: Whether carcinomas of the ampulla of Vater should be classified with biliary tract tumors and treated in a similar manner remains unknown. We sought to compare the outcomes of similarly staged periampullary adenocarcinomas (AAs) and analyze the chemotherapy responsiveness of AAs. PATIENTS AND METHODS: A total of 905 patients with resected periampullary adenocarcinomas were identified from a prospective surgical registry from 1988 to 2010. A second cohort of 64 metastatic AA patients from 1992 to 2009 who received either front-line fluoropyrimidine-based or gemcitabine-based chemotherapy was also identified. RESULTS: Overall survival (OS) for AAs was similar to survival with duodenal adenocarcinomas, but was significantly different from both extrahepatic biliary and pancreatic adenocarcinomas (P < 0.001 for each comparison). In multivariate analysis, AAs had a significantly improved OS in comparison with extrahepatic biliary adenocarcinomas (HR = 1.97, P = 0.006). Fluoropyrimidine-based as opposed to gemcitabine-based chemotherapy for metastatic AAs resulted in a significant improvement in time to progression (P = 0.001) but only a trend toward benefit for OS (P = 0.07) in multivariate analysis. CONCLUSIONS: Differences in the natural history of ampullary and extrahepatic biliary adenocarcinomas exist. Analyses of metastatic ampullary adenocarcinomas suggest that fluoropyrimidine-based chemotherapy may represent a more appropriate front-line chemotherapy approach.
BACKGROUND: Whether carcinomas of the ampulla of Vater should be classified with biliary tract tumors and treated in a similar manner remains unknown. We sought to compare the outcomes of similarly staged periampullary adenocarcinomas (AAs) and analyze the chemotherapy responsiveness of AAs. PATIENTS AND METHODS: A total of 905 patients with resected periampullary adenocarcinomas were identified from a prospective surgical registry from 1988 to 2010. A second cohort of 64 metastatic AA patients from 1992 to 2009 who received either front-line fluoropyrimidine-based or gemcitabine-based chemotherapy was also identified. RESULTS: Overall survival (OS) for AAs was similar to survival with duodenal adenocarcinomas, but was significantly different from both extrahepatic biliary and pancreatic adenocarcinomas (P < 0.001 for each comparison). In multivariate analysis, AAs had a significantly improved OS in comparison with extrahepatic biliary adenocarcinomas (HR = 1.97, P = 0.006). Fluoropyrimidine-based as opposed to gemcitabine-based chemotherapy for metastatic AAs resulted in a significant improvement in time to progression (P = 0.001) but only a trend toward benefit for OS (P = 0.07) in multivariate analysis. CONCLUSIONS: Differences in the natural history of ampullary and extrahepatic biliary adenocarcinomas exist. Analyses of metastatic ampullary adenocarcinomas suggest that fluoropyrimidine-based chemotherapy may represent a more appropriate front-line chemotherapy approach.
Authors: Donna E Hansel; Anirban Maitra; John W Lin; Michael Goggins; Pedram Argani; Charles J Yeo; Steven Piantadosi; Steven D Leach; Andrew V Biankin Journal: J Clin Oncol Date: 2005-03-20 Impact factor: 44.544
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Hari Nathan; Timothy M Pawlik; Christopher L Wolfgang; Michael A Choti; John L Cameron; Richard D Schulick Journal: J Gastrointest Surg Date: 2007-09-05 Impact factor: 3.452
Authors: Michelle D Reid; Serdar Balci; Nobuyuki Ohike; Yue Xue; Grace E Kim; Takuma Tajiri; Bahar Memis; Ipek Coban; Anil Dolgun; Alyssa M Krasinskas; Olca Basturk; David A Kooby; Juan M Sarmiento; Shishir K Maithel; Bassel F El-Rayes; Volkan Adsay Journal: Mod Pathol Date: 2016-09-02 Impact factor: 7.842
Authors: Manju D Chandrasegaram; Anthony J Gill; Jas Samra; Tim Price; John Chen; Jonathan Fawcett; Neil D Merrett Journal: World J Gastrointest Oncol Date: 2017-10-15
Authors: Michael J Overman; Jiexin Zhang; Scott Kopetz; Michael Davies; Zhi-Qin Jiang; Jiang Zhi-Qin; Katherine Stemke-Hale; Petra Rümmele; Christian Pilarsky; Robert Grützmann; Stanley Hamilton; Rosa Hwang; James L Abbruzzese; Gauri Varadhachary; Bradley Broom; Huamin Wang Journal: PLoS One Date: 2013-06-11 Impact factor: 3.240
Authors: Zon Weng Lai; Louisa Bolm; Hannah Fuellgraf; Martin L Biniossek; Frank Makowiec; Ulrich Theodor Hopt; Martin Werner; Tobias Keck; Dirk Bausch; Claudio Sorio; Aldo Scarpa; Oliver Schilling; Peter Bronsert; Ulrich Friedrich Wellner Journal: BMC Cancer Date: 2016-03-08 Impact factor: 4.430
Authors: Kathryn J Schunke; Lauren M Rosati; Marianna Zahurak; Joseph M Herman; Amol K Narang; Irina Usach; Alison P Klein; Charles J Yeo; Larry T Korman; Ralph H Hruban; John L Cameron; Daniel A Laheru; Ross A Abrams Journal: Adv Radiat Oncol Date: 2017-08-03